Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 1,307 trials

Patient-Controlled Sedation for Perineal Laceration Repair

We are studying if adding propofol sedation improves comfort for women during the repair of grade I and II obstetric perineal lacerations. This trial aims to see if it reduces pain and discomfort compared to standard care.

Obstetric Perineal Lacerations6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOtolaryngology

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Triple Negative Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.

Triple Negative Metastatic Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Prostate Cancer: ADT with Darolutamide

We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Prostate Cancer1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncology

Thromboprophylaxis for Advanced Germ Cell Tumors

We are studying a preventive treatment for patients with advanced germ cell tumors undergoing chemotherapy to see if it can help reduce the risk of blood clots. The trial also looks at the safety and cost-effectiveness of this treatment.

Testicular Germ Cell Tumor3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Cardiovascular Safety: BI 456906 for Overweight Individuals

We are testing a new medication for people with overweight or obesity and cardiovascular disease to see if it is as safe as a placebo. The study will also look at its effects on blood pressure and waist size.

Obesity>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Eptinezumab for Pediatric Migraine Prevention

We are studying whether eptinezumab can help reduce the number of migraine days in children and teenagers with episodic migraines. This trial aims to find out if it is a safe and effective option for young patients.

MigraineConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPediatrics

Late-onset Pompe Disease: Cipaglucosidase Alfa and Miglustat Study

We are evaluating the safety and effectiveness of a new treatment for children with late-onset Pompe disease. This study aims to understand how well the medications work together and their effects on young patients.

Late-onset Pompe Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyHematologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Osteoporosis: Zoledronate After Denosumab

We are studying if zoledronate can prevent bone loss in patients with osteoporosis who have stopped denosumab treatment. This trial also looks at how this treatment affects muscle strength and insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngology

Nipocalimab for Pregnancies at Risk of Severe Hemolytic Disease

We are studying whether Nipocalimab can help reduce the risk of fetal anemia in pregnant individuals at risk for severe hemolytic disease of the fetus and newborn. This trial compares the treatment to a placebo to assess its effectiveness.

Hemolytic Disease of the Fetus and Newborn>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin Study

We are studying a new treatment, Zilovertamab Vedotin, combined with standard care for patients with relapsed or refractory diffuse large B-cell lymphoma. The aim is to evaluate its safety and effectiveness compared to current therapies.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Vulvar Carcinoma: Chemoradiation vs. Neoadjuvant Chemotherapy

We are comparing two treatment approaches for locally advanced vulvar carcinoma to see which is more effective and safe. We also want to understand how these treatments impact quality of life and the influence of HPV status.

LAVC (Locally Advanced Vulvar Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visitsStandard MedicinesDermatologyPediatrics